drugset / Trial / NCT03747497

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

NCT03747497

Phase 2 Completed 196 enrolled MicuRx
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether contezolid acefosamil is as safe and effective as linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections

Timeline

Start
2018-11-15
Primary completion
2019-03-26
Completion
2019-03-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linezolid Other / unclassified 600 mg Intravenous
Subject contezolid acefosamil Unknown 1300 mg Intravenous